论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
晚期卵巢癌细胞减灭术中肝门淋巴结切除:必要与否?
Authors Huang H, Wei R, Long Y, Mo Y, Xie Y , Yao D
Received 20 August 2021
Accepted for publication 12 October 2021
Published 20 October 2021 Volume 2021:13 Pages 7981—7988
DOI https://doi.org/10.2147/CMAR.S334658
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yong Teng
Objective: This review aims to clarify the necessity of hepatic hilar lymph node resection on advanced ovarian cancer patients.
Background: PARP inhibitors and surgery have significantly improved the survival of patients with ovarian cancer. However, for patients with advanced ovarian cancer, there are often extensive epigastric disseminated metastatic lesions, especially the lymph nodes in the hepatic hilar area. Because of the complicated anatomical relationship and lack of experience in this area, this is easily ignored by gynecological oncologists.
Methods: Through the retrieval and analysis of the current database, namely PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Wangfang, etc., the literature regarding this topic published before March 2021 were thoroughly investigated.
Conclusion: For the hepatic hilar regional lymph node surgery, through careful preoperative evaluation, surgical-indication clarification, appropriate case selection, standardized surgical operations and multidisciplinary cooperation with general surgeons, the prognosis of patients is significantly improved. Postoperative complications are also safe and controllable and convincing. To conclude, the application of hilar region lymph node cytoreductive surgery for patients with advanced ovarian cancer is a feasible and preferred choice.
Keywords: advanced ovarian cancer, hilar lymph node, cytoreductive surgery